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Abstract
Background: Cardiovascular magnetic resonance (CMR) can provide quantitative data of the
myocardial tissue utilizing high spatial and temporal resolution along with exquisite tissue contrast.
Previous studies have correlated myocardial scar tissue with the occurrence of ventricular
arrhythmia. This study was conducted to evaluate whether characterization of myocardial
infarction by CMR can predict cardiovascular events in patients with ischemic cardiomyopathy
(ICM).
Results: We consecutively studied 86 patients with ICM (LVEF < 50%, mean LVEF: 26 ± 12%) with
CMR before revascularization or medication therapy ± implantable cardiac defibrillator,
determined the amount of myocardial scar, and followed for development of cardiovascular events.
Thirty-three patients (38%) had cardiovascular events (mean follow-up: 20 ± 16 months). Patients
who developed cardiovascular eve n t s  h a d  l a r g e r  s c a r  v o l u m e  a n d  s c a r  p e r c e n t a g e  o f  t h e
myocardium than those who did not develop cardiovascular events (16.8 ± 12.4 cm3 vs. 11.7 ± 12.6
cm3, p = 0.023 and 10.2 ± 6.9% vs. 7.2 ± 6.7%, p = 0.037, respectively). There were no significant
differences in LVEDV, LVESV and LVEF between the patients with and without cardiovascular
events (231 ± 76 ml vs. 230 ± 88 ml; 180 ± 73 ml vs. 175 ± 90 ml; and 25 ± 10% vs. 27 ± 13%,
respectively).
Conclusion: Quantification of the scar volume and scar percentage by CMR is superior to LVEDV,
LVESV, and LVEF in prognosticating the future likelihood of the development of cardiovascular
events in patients with ICM.
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Background
Congestive heart failure (CHF) has become a widespread
public health concern, affecting approximately 5 million
patients in the United States. Over 550,000 new cases and
300,000 deaths are reported annually [1]. The most com-
mon cause of CHF is coronary artery disease. Of these, the
highest mortality rate is seen in patients with ischemic car-
diomyopathy (ICM) [2]. The high morbidity and mortal-
ity in CHF have been associated with a high incidence of
ventricular arrhythmia and left ventricular (LV) remodel-
ling [3,4]. Post infarction LV remodelling provides a sub-
strate to trigger high-grade ventricular arrhythmia [5].
Specifically, areas of peri-infarct ischemia have been
shown to be arrhythmogenic. It has been well known that
revascularization of these ischemic territories results in a
lower incidence of ventricular arrhythmia in patients with
ICM [6-9]. Similarly, scar tissue has been associated with
ventricular arrhythmia [10-12]. Previous studies have
reported that myocardial scar as assessed by cardiovascu-
lar magnetic resonance (CMR), is more accurate than tra-
ditional measurements including left ventricular ejection
fraction (LVEF) in identifying patients who develop ven-
tricular arrhythmia [13-17]. However, these studies were
not conducted in patients with significantly compromised
LV function, who are most predisposed to developing car-
diovascular events, including ventricular arrhythmia,
pathological remodelling and worsening CHF. Further-
more, prognostic relationship between transmurality of
the scar and occurrence of cardiovascular events in
patients with ICM was not investigated. In order to
address these issues, we systematically analyzed multiple
imaging parameters generated from CMR to determine
whether the characterization and quantitation of myocar-
dial infarction (MI) by CMR can predict cardiovascular
events in patients with ICM.
Methods
Patient population
Eighty-six patients (73 men, 13 women; mean age 57 ± 12
years) with coronary artery disease and LV dysfunction
(LVEF < 50%, mean LVEF was 26 ± 12%) scheduled to
undergo either revascularization or medical therapy ±
implantable cardiac defibrillator (ICD) placement were
recruited consecutively for CMR. All patients underwent
diagnostic coronary angiography before CMR examina-
tion. After CMR examination and assessment of total
myocardial scar volume, all the patients were followed for
the presence of cardiovascular events, as described below.
35 patients underwent revascularization (26 patients cor-
onary artery bypass surgery (CABG) and 9 percutaneous
coronary intervention (PCI) patients) ± ICD placement
and 51 patients received medical therapy ± ICD place-
ment. All patients had previous MI. But patients with
acute infarction (within seven days), unstable angina pec-
toris, asthma, pulmonary disease, severe valvular disease,
or contraindications to the CMR examination were
excluded. The study protocol was approved by the human
subjects committee at Stanford university.
Imaging protocols
All images were acquired on a 1.5-Tesla whole-body scan-
ner (Signa, GE Healthcare, Milwaukee, WI) with the
patient in a supine position using an 8-element phased-
array radiofrequency coil with breath-holding and cardiac
gating. Cine images of the LV in short and long axes were
acquired using a steady-state free precession sequence
(SSFP, TR 3.8, TE 1.6, FA 45°, slice thickness 10 mm, slice
gap 0). Late gadolinium enhancement (LGE) images (seg-
mented k-space inversion recovery sequence, TR 7.1, TE
3.1, TI 200–250, slice thickness 10 mm, slice gap 0) were
acquired throughout the entire LV starting at 20 min, fol-
lowing administration of 0.2 mmol/kg of gadolinium
diethytriaminepentaacetic acid (Gd-DTPA, Magnevist®,
Schering AG, Germany). The inversion time set to null the
signal of normal myocardium after Gd-DTPA administra-
tion was adjusted during the course of the scan as neces-
sary.
Image analysis
Images were analyzed using MASS analysis software
(MASS Analysis Plus Version 5.1, Leiden University).
Automatic tracing with manual adjustment of endocardial
and epicardial borders from short-axis images was per-
formed to calculate left ventricular end-diastolic volume
(LVEDV), left ventricular end-systolic volume (LVESV),
and LVEF.
Assessment of myocardial infarction by Late Gadolinium 
Enhancement
The short-axis LGE images were evaluated for the presence
of scar and traced manually to measure total scar volume.
An infarct region was defined as an area of hyperenhance-
ment, with a higher signal intensity (≥ 2 SD) compare to
remote region in the same slice [13]. Myocardial and scar
volume were calculated (myocardial or scar area × slice
thickness of 10 mm). The scar percentage of myocardial
volume was also expressed as percentage of the total myo-
cardial volume (scar volume/myocardial volume × 100)
as shown in figure 1. We analyzed contrast-enhanced
images using the 72-segment model in which the left ven-
tricle was divided into 12 circumferential segments in six
short-axis views [18]. In patients with microvascular
obstruction, these hypointense areas were included as scar
area. Isolated midwall or subepicardial hyperenhance-
ment was excluded because this was not considered as scar
area [19,20]. The transmural extent of hyperenhancement
was graded as a percentage of scar tissue in each segment:
0%, 1 to 25%, 26 to 50%, and 51 to 75% (non-transmu-
ral); and 76 to 100% (transmural).Journal of Cardiovascular Magnetic Resonance 2008, 10:17 http://www.jcmr-online.com/content/10/1/17
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Results
Patient characteristics
Clinical characteristics of the study population are sum-
marized in table 1. Thirty-five patients were revascularized
(26 CABG, 9 PCI patients). Clinical follow-up over a
period of 20 ± 16 months (minimum period was 1
month, maximum period was 56 months) was obtained
in all patients. Twenty-four of the 86 patients (28%) had
2 vessel disease (left main, or two vessel with proximal left
anterior descending artery), and 49 patients (57%) had 3
vessel disease. During the follow-up period, 33 patients
(38%) had cardiovascular events (mean follow-up period
was 20 ± 16 months). Fifteen patients of the 33 patients
had CHF, 9 patients had ventricular arrhythmia, 2
patients had syncope, 2 patients had MI, 5 patients
needed revascularization and 6 patients died due to cardi-
ovascular cause during the follow-up period. There were
any deaths or events were related to revascularization pro-
cedures.
Cardiac magnetic resonance parameters to predict 
cardiovascular events
CMR parameters among the patients ± cardiovascular
events are summarized in table 2. Both mean scar volume
and scar percentage of the myocardium were larger in
patients with cardiovascular events than those without
cardiovascular events (16.8 ± 12.4 cm3 vs. 11.7 ± 12.6
cm3, p = 0.023 and 10.2 ± 6.9% vs. 7.2 ± 6.7%, p = 0.037,
respectively). There were no significant differences in
LVEDV, LVESV and LVEF between the patients with and
without cardiovascular events (234 ± 76 ml vs. 230 ± 88
ml, 180 ± 73 ml vs. 175 ± 90 ml, 25 ± 10% vs. 27 ± 13%,
respectively).
The transmurality of the scar was also analyzed by divid-
ing into non-transmural vs. transmural extent of MI (1–
75% vs. 76–100%, respectively) among the patients as
shown in table 3. Patients with cardiovascular events had
larger number of non-transmural segments than patients
without cardiovascular events (18.4 ± 14.0% vs. 13.8 ±
11.2%, p = 0.049). Specifically, higher incidences of cardi-
ovascular events were seen in the 26–50% non-transmu-
ral segments (9.2 ± 10.6% vs. 3.2 ± 3.6%, p = 0.03). In
Cardiac magnetic resonance characterization of myocardial infarction Figure 1
Cardiac magnetic resonance characterization of myocardial infarction. The total myocardial and scar area in each of 
the 8 to 11 short-axis images were traced manually. Myocardial and scar volume for each slice were calculated as (area myo-
cardium or area scar × slice thickness of 10 mm). The scar percentage of myocardium was also expressed as a percentage of 
the total myocardial volume (Volume scar/Volume myocardium × 100).
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Table 1: Clinical profile of patients
All (n = 86) Revascularization (n = 35) No Revascularization (n = 51) p-value
Age, years 57 ± 12 58 ± 11 57 ± 14 0.32
Gender, male 73 (85%) 32 (91%) 41 (80%) 0.16
History of hypertension 54 (63%) 26 (74%) 28 (55%) 0.07
History of HL 59 (69%) 25 (71%) 34 (67%) 0.64
History of diabetes 24 (28%) 11 (31%) 13 (25%) 0.55
History of smoking 26 (30%) 12 (34%) 14 (27%) 0.50
Beta Blocker Use 62 (78%) 27 (90%) 35 (71%) 0.06
Ace-I or ARB Use 45 (57%) 17 (57%) 28 (57%) 0.36
Coronary anatomy, n (%)
1 vessel disease 13 (15%) 3 (9%) 10 (20%) 0.16
2 vessels disease† 24 (28%) 7 (21%) 17 (33%) 0.17
3 vessels disease 49 (57%) 25 (71%) 24 (47%) 0.02
ICD placement (%) 31 (36%) 8 (23%) 24 (47%) 0.02
Scar volume (cm3) 13.7 ± 12.7 14.5 ± 12.0 13.1 ± 13.3 0.60
Scar % of myocardium (%) 8.3 ± 6.9 9.2 ± 7.6 7.8 ± 6.3 0.37
LVEF (%) 26 ± 12 29 ± 13 24 ± 11 0.10
LVEDV (ml%) 231 ± 83 230 ± 97 232 ± 73 0.88
LVESV (ml%) 177 ± 83 173 ± 96 180 ± 74 0.69
LVED mass/volume (g/ml) 0.79 ± 0.30 0.83 ± 0.28 0.77 ± 0.31 0.22
Ant, sep infarct lesion 55 (64%) 23 (66%) 32 (63%) 0.78
Lat infarct lesion 40 (47%) 16 (46%) 24 (47%) 0.53
Inf infarct lesion 63 (73%) 25 (71%) 38 (75%) 0.75
Cardiovascular events 33 (38%) 16 (46%) 17 (33%) 0.24
Values are expressed as a mean ± SD. HL = hypercholesterolemia;
Ace-I = Angiotensin Converting Enzyme – Inhibitor, ARB = Angiotensin Receptor Blocker ICD = implantable cardiac defibrillator; LVEF = left 
ventricular ejection fraction;
LVEDV = left ventricular end diastolic volume; LVESV = left ventricular end systolic volume;
† 2 vessel disease include P-LAD or LMT.
Table 2: Predictors of cardiovascular events
Cardiovascular events (+) Cardiovascular events (-) p – value
Scar volume (cm3) 16.8 ± 12.4 11.7 ± 12.6 0.023
Scar % of the myocardium (%) 10.2 ± 6.9 7.2 ± 6.7 0.037
LVEF (%) 25 ± 10 27 ± 13 0.26
LVEDV (ml) 234 ± 76 230 ± 88 0.41
LVESV (ml) 180 ± 73 175 ± 90 0.40
LVED mass/volume (g/ml) 0.73 ± 0.25 0.84 ± 0.32 0.06
Values are expressed as a mean ± SD. LVEF = left ventricular ejection fraction; LVEDV = left ventricular end diastolic volume; LVESV = left 
ventricular end systolic volume.
Table 3: The proportion of non-transmural vs. transmural segments of myocardial infarction
Cardiovascular events (+) Cardiovascular events (-) p – value
Non-transmural MI (1–75% scar of myocardium) 18.4 ± 14.0 13.8 ± 11.2 0.049
1 – 25% scar of myocardium 9.2 ± 11.0 6.7 ± 9.3 0.12
26 – 50% scar of myocardium 9.2 ± 10.6 3.2 ± 3.6 0.03
51 – 75% scar of myocardium 3.5 ± 4.2 4.0 ± 4.5 0.30
Transmural MI (76–100% scar of myocardium) 5.8 ± 10.2 7.2 ± 11.4 0.28
Values are expressed as a mean ± SD.Journal of Cardiovascular Magnetic Resonance 2008, 10:17 http://www.jcmr-online.com/content/10/1/17
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subanalysis, there were no significant difference in the
number of both non-transmural segments and transmural
segment in patients with and without ventricular arrhyth-
mia (p = 0.71, p = 0.64, respectively). In addition, there
were no significant difference in the number of both non-
transmural segment and transmural segment in patients
with and without worsening CHF (p = 0.94, p = 0.06,
respectively).
Correlation between scar characteristics and functional 
parameters
The correlation of LVEF, LVEDV and LVESV with scar vol-
ume and scar percentage of the myocardium is shown in
figure 2, 3, 4 (figure 2: LVEF, figure 3: LVEDV, figure 4:
LVESV). These measurements did not correlate with scar
volume with r values of 0.16, 0.08 and 0.10, respectively
and did not correlate with scar percentage of the myocar-
dium with r values of 0.08, 0.01 and 0.02, respectively.
Effects of revascularization
When the patients were analyzed between the revascular-
ization (CABG or PCI ± ICD placement) and the no revas-
cularization groups (medical therapy ± ICD placement),
there were more patients with 3 vessel disease and with
ICD placement who underwent revascularization (p =
0.02, for each) as shown in table 1. However, there was no
significant difference in both scar volume and percentage
of the myocardium between the 2 groups (p = 0.60 and
0.37, respectively). Finally, there was no significant differ-
ence in the incidence of cardiovascular events between
these two groups (p = 0.24).
Clinical parameters to predict cardiovascular events
Analyses of clinical characteristics of all patients with and
without cardiovascular events are summarized in table 4.
There was no significant difference in clinical parameters
between these two groups.
Discussion
Patients surviving MI and developing chronic ICM are at
risk for developing cardiovascular events. However, not
all patients with chronic ICM have similar risk profiles.
Traditional clinical indicators (LVEF, NYHA functional
class, and coronary anatomy) and electrocardiographic
markers (QRS duration, T-wave alternans, and signal aver-
age ECG) have been used to identify patients at risk for
developing ventricular arrhythmia and sudden death
[21,22]. However, these markers have low predictive
value. They are descriptors of myocardial and electrical
dysfunctions rather than specific physiologic markers to
identify patients at risk for developing cardiovascular
events[21]. This is the first study to confirm that the quan-
titation of the scar volume and percentage by CMR can
predict the development of cardiovascular events in
patients with ICM. The traditional risk factors including
LVEF, LVEDV, and LVESV did not differentiate the patients
who did and did not develop cardiovascular events. Fur-
thermore, these parameters did not correlate with the
quantitative characterizations of myocardial infarction by
CMR.
Based on our study, a more detailed analysis of the injured
myocardium using CMR may predict the future occur-
rence of cardiovascular events in patients with ICM. We
have performed an extensive analysis of image-based data
using CMR to identify specific tissue characteristics of the
infarcted myocardium that may serve as a longitudinal
prognostic marker for developing cardiovascular events in
patients with ICM. In addition to the scar volume and per-
centage, patients with non-transmural segments had
developed more cardiovascular events than patients with
transmural segments. Recent studies indicate that injured
but viable myocytes in the peri-infarct territory consistent
with non-transmural infarction may lead to cardiovascu-
lar events [23,24]. The presence of residual viable myocar-
dium, as a path of conduction and/or site of peri-infarct
The correlation between left ventricular volumes and the  scar volume and scar percentage Figure 2
The correlation between left ventricular volumes 
and the scar volume and scar percentage. The correla-
tion of LVEF with scar volume (a) and scar percentage of the 
myocardium (b).
(a)
R   0.16  
(b)  
R   0.08 Journal of Cardiovascular Magnetic Resonance 2008, 10:17 http://www.jcmr-online.com/content/10/1/17
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The correlation between left ventricular volumes and the  scar volume and scar percentage Figure 4
The correlation between left ventricular volumes 
and the scar volume and scar percentage. The correla-
tion of LVESV with scar volume (a) and scar percentage of 
the myocardium (b).
(a)
R   0.10 
100      200      300      400      500     600      700     800      900 
                                    L VESV (ml) 
(b) 
R   0.02 
The correlation between left ventricular volumes and the  scar volume and scar percentage Figure 3
The correlation between left ventricular volumes 
and the scar volume and scar percentage. The correla-
tion of LVEDV with scar volume (a) and scar percentage of 
the myocardium (b).
(a)
(b) 
R   0.01 
Table 4: Predictors of cardiovascular events
Cardiovascular events (+) (n = 33) Cardiovascular events (-) (n = 53) p-value
Age, years 56 ± 13 58 ± 12 0.18
Gender, male 28 (85%) 45 (85%) 0.99
History of hypertension 22 (67%) 32 (60%) 0.56
History of hyperlipidemia 22 (67%) 37 (70%) 0.76
History of diabetes 11 (33%) 13 (25%) 0.38
Beta Blocker Use 25 (81%) 37 (77%) 0.10
Ace-I or ARB Use 18 (58%) 27 (56%) 0.25
History of smoking 13 (39%) 13 (25%) 0.14
Coronary anatomy, n (%)
1 vessel disease 3 (9%) 10 (19%) 0.22
2 vessels disease 10 (30%) 14 (26%) 0.70
3 vessels disease 20 (61%) 29 (55%) 0.59
Values are expressed as a mean ± SD. Ace-I = Angiotensin Converting Enzyme – Inhibitor, ARB = Angiotensin Receptor BlockerJournal of Cardiovascular Magnetic Resonance 2008, 10:17 http://www.jcmr-online.com/content/10/1/17
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ischemia, may be a necessary cofactor in the pathogenesis
of cardiovascular events, a conclusion that has been
reported in previous studies [23,24]. Ejection fraction is
good predictor of cardiovascular events, but it could not
reveal all of LV remodeling. Therefore, a more precise pre-
dictor may be possible when both infarct size and pres-
ence of peri-infarct injury can be considered through a
more quantitative evaluation of the non-transmural
extent of MI.
Conclusion
Quantitative characterization of the scar volume and per-
centage by CMR is superior to LVEDV, LVESV, and LVEF in
prognosticating the future likelihood of the development
of cardiovascular events in patients with ICM. This patient
population could benefit from this study in which the scar
volume and percentage measured by CMR has been vali-
dated as a quantitative prognostic marker.
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